RxDoctor Payments Data

Imad Ahmed, MD

Nephrology · Amherst, NYNPI 1912118431

Payments from drug & device makers

$800in general payments, 2019–2025

Across 46 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$194
  • Travere Therapeutics, Inc.$141
  • Akebia Therapeutics Inc$135
  • Otsuka America Pharmaceutical, Inc.$122
  • E.r. Squibb & Sons, L.L.C.$88
  • Mallinckrodt Enterprises LLC$27
  • plus $92 from 5 others

What the payments were for

  • Food & beverage$58273%
  • Education$21827%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$800 in reported general payments places this provider in the 50th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York

Medicare billing

Part B allowed, 2024
$176,726
Medicare patients
302
Services billed
1,753

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin90$99,807
FarxigaDapagliflozin Propanediol75$98,223
LokelmaSodium Zirconium Cyclosilicate96$67,198
VeltassaPatiromer Calcium Sorbitex35$49,374
ProcritEpoetin Alfa23$23,421
ClinolipidFat Emulsion/Olive/Soy/Phospho43$17,566
RetacritEpoetin Alfa-Epbx14$6,064
Sevelamer Carbonate54$5,880
SpsSodium Polystyrene Sulfon/Sorb56$5,249
Calcitriol378$4,204
Febuxostat11$2,328
Telmisartan51$2,078
Calcium Acetate16$1,645
Hydralazine Hcl96$1,356
Spironolactone116$1,285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerRetacrit$16$6,06414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 935 nephrology providers in New York.

Other nephrology in Amherst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →